Skip to main
PHVS

Pharvaris B.V. (PHVS) Stock Forecast & Price Target

Pharvaris B.V. (PHVS) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 20%
Buy 70%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Pharvaris is a late-stage biopharmaceutical company that specializes in developing novel, oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE) attacks. Their main pipeline candidate, deucrictibant, has shown positive data in both Phase 2 prophylaxis and on-demand studies in HAE. While there are potential risks in focusing on one mechanism of action and therapeutic indication, Pharvaris has discussed exploring other B2-receptor-mediated diseases, providing some therapeutic diversification. With their current financials and ongoing clinical trials, Pharvaris has the potential to gain market share in the maturing HAE therapeutic landscape, but may need to differentiate deucrictibant from other available options. The success of their ongoing Phase 3 study and subsequent regulatory approvals will be key factors in their future commercial success.

Bears say

Pharvaris is a late-stage biopharmaceutical company with a negative outlook due to concerns about the success of their upcoming CHAPTER-3 data readout for their drug deucrictibant in the prophylactic setting. While there are similarities between their Phase 2 study and CHAPTER-3, there is still uncertainty about the drug's ability to effectively reduce attack rates. If efficacy falls short and the prophy opportunity is removed, the company's fair value could decrease to $29/share. Furthermore, the company's planned launch of deucrictibant in mid-2027 and introduction of FY33 estimates indicate a longer timeline for potential profitability, which could impact investor confidence.

Pharvaris B.V. (PHVS) has been analyzed by 10 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 70% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pharvaris B.V. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pharvaris B.V. (PHVS) Forecast

Analysts have given Pharvaris B.V. (PHVS) a Buy based on their latest research and market trends.

According to 10 analysts, Pharvaris B.V. (PHVS) has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pharvaris B.V. (PHVS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.